- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6287
Provisional Schedule
- Committee meeting:
- 12 November 2025
- Expected publication:
- 22 April 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Amgen (sotorasib)
- Others
- Department of Health and Social Care
- NHS England
- Professional groups
- Association of Cancer Physicians
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Boehringer Ingelheim (nintedanib) - not participating
- Bristol-Myers Squibb (adagrasib, subject to NICE evaluation)- not participating
- Hospira UK (docetaxel) - not participating
- Seacross Pharmaceuticals (docetaxel) - not participating
- General commentators
- All Wales Therapeutic and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 April 2025 | Invitation to participate |
| 24 February 2025 - 25 March 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 15 March 2024 | Please note that following on from information received from the company, which NICE and NHS England must now consider, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 16 January 2024 - 13 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 16 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 16 January 2024 | In progress. Draft scope documents issued. |
For further information on our processes and methods, please see our CHTE processes and methods manual